ORANGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today released its 2024 Impact Report outlining how it continued to deliver high-quality, personalized care to seniors while creating a positive impact on its members, providers, employees and the communities it serves.
"As America's senior population rapidly grows, Alignment Healthcare is redefining what's possible in health care by combining compassion, innovation and accountability," said John Kao, founder and CEO, Alignment Healthcare. "Our Impact Report reflects our commitment to putting seniors first, empowering providers, leveraging data-driven care, and leading with a serving heart to create a better way to age in America."
Noteworthy Highlights from the 2024 Impact Report include:
Better Access to Care
Improved Health Outcomes
Delivery of Innovative, Data-Driven Care
Increased Quality and Member Satisfaction
Commitment to Employees and Serving Responsibly
The 2024 Impact Report reinforces Alignment's mission to provide compassionate, personalized care that addresses the holistic needs of America’s growing senior population. To learn more, visit https://www.alignmenthealth.com/impact/.
About Alignment Health
Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.
Media Contact
Priya Shah
mPR, Inc. for Alignment Health
This email address is being protected from spambots. You need JavaScript enabled to view it.
1 US EPA. (2025, February 24). Greenhouse Gas Equivalencies Calculator. US EPA. https://www.epa.gov/energy/greenhouse-gasequivalencies-calculator

| Last Trade: | US$19.21 |
| Daily Change: | -0.15 -0.77 |
| Daily Volume: | 1,813,631 |
| Market Cap: | US$3.840B |
November 19, 2025 October 30, 2025 September 08, 2025 August 27, 2025 July 30, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load